Docs try to close info gap on kids' meds

Nov 23, 2007

Ten years after the U.S. government began trying to ensure children's prescription drugs were safe, doctors still have little information to guide them.

While federal regulators have induced pharmaceutical companies to conduct hundreds of studies on some 200 drugs, another two-thirds of the thousands of children's medicines remain untested, The Washington Post reported Friday.

"Are there children dying because of this? I don't know. Are there children being less effectively treated because of this? Probably, yes," Richard Gorman of the American Academy of Pediatrics said in the Post. "That's the problem: We don't know what we don't know."

The gap in medical knowledge has varied roots. Testing of drugs on children was deemed unnecessary and unethical for decades; government and drug houses provided inadequate funding; and medical testing on children is difficult.

One help was the 2003 Pediatric Research Equity Act, which authorized the Food and Drug Administration to require companies to test new drugs on before they are approved for sale and provided incentives for drug companies to conduct studies, enabling the FDA to give doctors specific advice on at least 138 drugs, the Post said.

Copyright 2007 by United Press International

Explore further: Flu vaccine may hold key to preventing heart disease

add to favorites email to friend print save as pdf

Related Stories

US secretly created 'Cuban Twitter' to stir unrest

Apr 03, 2014

In July 2010, Joe McSpedon, a U.S. government official, flew to Barcelona to put the final touches on a secret plan to build a social media project aimed at undermining Cuba's communist government.

Recommended for you

Supercomputers link proteins to drug side effects

20 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments : 0